Skip to main content
Equibles
NAMS logo

NAMS · NewAmsterdam Pharma Co N.V. · Metrics

Track NAMS — free

Use NAMS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NAMS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$21.38 +0.91 (+4.42%)
Rebalance outlook locked
Market Cap
$2.45B
Shares
119.54M
Volume · Oct 20 434.59K Avg daily vol (3M) 1.4M

NAMS metrics

85 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$20.47
Market cap
$2.45B

Price action

20 metrics
Price change (1W)
-3.7%
Price change (30D)
-9.3%
Price change (3M)
-31.0%
Price change (6M)
-39.5%
Price change (YTD)
-41.6%
Price change (1Y)
-43.8%
Trailing year
Price change (5Y)
+109.1%
52-week high
$41.45
52-week low
$19.83
Change from 52-week high
-50.6%
Change from 52-week low
+3.2%
Annualized volatility
52.7%
Annualized volatility (3M)
49.9%
Beta
1.3
RSI (14D)
37.2
Price vs SMA 50
-15.0%
Price vs SMA 200
-32.7%
Avg volume (3M)
1.40M
Relative volume
0.5
Average dollar volume
$34.71M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
119.54M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
243.9×
reciprocal yield 0.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
332.9×
reciprocal yield 0.3%
P / book
3.8
reciprocal yield 26.6%
FCF yield
-6.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
139.9×
reciprocal yield 0.7%
EV / revenue historical average (5Y)
139.9×
reciprocal yield 0.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
-3,432.2%
Trailing 12 months
Net margin
-3,644.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$244.41M
Net income (TTM)
−$259.50M
Trailing 12 months
Diluted EPS (TTM)
$-2.15
FCF margin
-2,018.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.06
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.02
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-2.15
Operating cash flow per diluted share (TTM)
$-1.19
Free cash flow per diluted share (TTM)
$-1.19
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$1.23
Stock compensation per diluted share (TTM)
$0.54
Book value per share
$5.97

Growth

11 metrics
Revenue growth YoY
-80.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$7.12M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.1%
Year over year · more shares
Revenue CAGR (3Y)
-39.7%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-41.1%
Return on assets
-36.8%
Debt / equity
0.0
Current ratio
9.0
EBITDA (TTM)
−$244.16M
Free cash flow (TTM)
−$143.72M
Quick ratio
9.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$633.85M
Latest balance sheet
Cash & equivalents
$424.15M
Total assets
$704.45M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$143.46M
Capital expenditures (TTM)
$260,000
R&D (TTM)
$149.25M
SG&A (TTM)
$102.28M
Stock compensation (TTM)
$65.42M
R&D / revenue
2,095.9%
Stock compensation / revenue
918.6%

Ownership (13F)

9 metrics
13F filers
200
13F filer change QoQ
+24
Institutional ownership
105.2%
Conviction holders (share of 13F filers)
6.6%
Crowding (high-turnover and private-fund holders)
48.8%
Private-fund adviser ownership
48.7%
Active holders' share change QoQ
+20.2%
Holder tenure
4.5
Price vs estimated holder cost
+86.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.1%

Short interest

3 metrics
Short interest
15.9%
Latest settlement · 9.4 days to cover
Days to cover
9.4d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$4.44M
Insider-sentiment score
75 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1936258 CUSIP N62509109 13F (30d) 7 filings 7 filers Visit website Investor relations